What is the recommended treatment for hives (urticaria) in an adult?

Treatment of Hives (Urticaria) in Adults

Start with a standard-dose second-generation H1-antihistamine (e.g., cetirizine, loratadine, fexofenadine) taken daily, and if symptoms persist after 2-4 weeks, increase the dose up to 4-fold rather than adding other medications. 1

First-Line Treatment: Second-Generation Antihistamines

Begin with a standard daily dose of a non-sedating second-generation H1-antihistamine. The 2022 international urticaria guidelines establish this as the foundation of treatment 1. These medications work by blocking histamine release from mast cells and basophils, which are the primary drivers of hive formation.

If symptoms are intolerable or inadequate control persists after 2-4 weeks, updose the same antihistamine up to 4 times the standard dose (e.g., cetirizine 40mg daily instead of 10mg) 1. This updosing strategy is more effective for achieving complete symptom control compared to combining multiple different antihistamines—40% vs. 10.7% complete control rates 2.

Key Points About Antihistamine Dosing:

• Updosing a single antihistamine 4-fold is superior to combining multiple antihistamines 2
• Both strategies achieve similar rates of "well-controlled" disease (57.7% vs. 46.4%), but updosing provides better complete control 2
• Continue high-dose antihistamines for at least 3 consecutive months of complete control before attempting to step down 1

What NOT to Do: Avoid Routine Corticosteroids

Do not routinely add systemic corticosteroids for acute urticaria or chronic urticaria flares. The evidence shows:

• Corticosteroids added to antihistamines provide minimal benefit—only a 2.2% absolute improvement in patients already likely to respond to antihistamines alone (NNT=45) 3
• They likely increase adverse events by 15% (NNH=9) 3
• Two out of three high-quality RCTs found no improvement when adding prednisone to antihistamines for acute urticaria 4
• Post-infectious and acute idiopathic urticaria—the most common causes—are not helped by steroids and may cause morbidity 5

Topical corticosteroids are similarly ineffective and should not be used 6.

Second-Line Treatment: Omalizumab

For patients who fail high-dose antihistamines after adequate trial (2-4 weeks at 4x dosing), omalizumab 300mg subcutaneously every 4 weeks is the recommended second-line therapy 1. This represents a major advance with 65-80% success rates 7.

Omalizumab Dosing Strategy:

• Start at 300mg every 4 weeks based on robust double-blind placebo-controlled trials 1
• Allow up to 6 months for response 1
• If insufficient response, updose by shortening intervals and/or increasing dose (maximum 600mg every 14 days) 1
• Higher doses are particularly beneficial in patients with high body mass index 1
• The safety profile at higher doses mirrors that of standard dosing 1

Third-Line Treatment: Cyclosporine

For patients unresponsive to high-dose omalizumab, cyclosporine is the third-line option with 70-80% success rates 1, 7. However, it requires careful monitoring:

• Monitor blood pressure and renal function (BUN, creatinine) every 6 weeks 1
• Potential risks include hypertension, renal dysfunction, hirsutism, and gum hypertrophy 1
• The risk-benefit profile is inferior to omalizumab but superior to extended corticosteroid use 1, 7

Treatment Algorithm Summary:

1. Step 1: Standard-dose second-generation H1-antihistamine daily
2. Step 2: Updose same antihistamine up to 4-fold (after 2-4 weeks if needed)
3. Step 3: Add omalizumab 300mg every 4 weeks (updose if needed up to 600mg every 14 days)
4. Step 4: Switch to cyclosporine with appropriate monitoring

Step-Down Approach

Once complete control is achieved (UCT score >16 for chronic urticaria), use an "as much as needed and as little as possible" approach 1:

• Wait at least 3 consecutive months of complete control before stepping down
• Reduce antihistamine dose by no more than 1 tablet per month 1
• If breakthrough symptoms occur, return to the last effective dose 1

Common Pitfalls to Avoid:

• Don't prescribe epinephrine auto-injectors for uncomplicated urticaria without evidence of anaphylaxis (hypotension, hypoxia) 5
• Don't perform extensive laboratory workups unless history/exam suggests specific underlying conditions 8
• Don't use first-generation antihistamines (diphenhydramine) as first-line due to sedation—reserve for acute severe cases only 4
• Don't mistake urticaria for an IgE-mediated allergy—this is almost never the cause of new-onset hives 5

Over 90% of patients can be successfully treated using this sequential approach 7, and more than half with chronic urticaria will have resolution or improvement within one year 8.